â??A study of Amrutadi Tablet and Arbudahara Tablet in treatment of cancer of mouth induced by gutkha chewing

â??A clinical study of amrutadi tablet and Arbudhara tablet in the adjuvant therapy of Squamous cell carcinoma w.s.r. to Gutkha induced oral cancer.

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2017/03/008127

Enrollment

Registered

2017-03-17

Start date

Unknown

Completion date

Unknown

Last updated

2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: null- Arbuda(Oral Cancer)

Interventions

Intervention1: Amrutadi Tablet, Arbudahara Tablet and Gargling: Amrutadi tablet which contains Amalaki, Guduchi, Yasthimadhu, Ashwagandha, Pippali, Shuddha guggulu and Tulsi which have immunostimulato

Eligibility

Inclusion criteria

Inclusion criteria: 1 Patient diagnosed as squamous cell carcinoma (gutkha induced oral cancer) after histopathological report & being submitted for radiotherapy or chemotherapy or both. 2 Acute and chronic disorders 3 Cancer stages 0,I,II according to TNM criteria are included.

Exclusion criteria

Exclusion criteria: Metastasis Patients suffering from severe systemic disorders and diseases like HIV, HbsAg etc

Design outcomes

Primary

Measure	Time frame
Improvment in immune system, Improvement in pain, difficulty in swallowingTimepoint: 8 weeks	—

Secondary

Measure	Time frame
Safety from other complicationsTimepoint: 8 weeks	—

Countries

India

Contacts

Public ContactDr Shilpa MP

Govt. Akhandanand Ayurved College & Hospital

sejharsh@gmail.com9824068760

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026